Actively Recruiting

Age: 18Years +
All Genders
ID06181994

Outcomes of Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma; Middle Meningeal Artery Embolization for Chronic Subdural Hematoma (MESH)

Led by Montefiore Medical Center · Updated on 2026-01-07

5000

Participants Needed

19

Research Sites

N/A

Total Duration

On this page

Sponsors

M

Montefiore Medical Center

Lead Sponsor

G

Geisinger Clinic

Collaborating Sponsor

AI-Summary

What this Trial Is About

Chronic subdural hematoma (cSDH) is a common neurosurgical condition characterized by blood buildup in the subarachnoid space, mainly affecting older adults and linked to serious health risks. Researchers are exploring the outcomes of treating cSDH with middle meningeal artery embolization (MMAE) to assess its clinical effectiveness, recurrence rates, and safety. This multi-center retrospective cohort study aims to evaluate whether MMAE shows a favorable safety profile with few treatment-related complications. The study observes adult patients who have undergone endovascular embolization of the middle meningeal artery using approved embolization materials such as PVA particles, Onyx, nBCA glue, dimethyl sulfoxide, microcoils, or combinations thereof. Participants have received this minimally invasive treatment, which is being assessed for its role in managing cSDH. No experimental interventions or control groups are involved as this is an observational study. Participants are monitored for reaccumulation of hematoma and the need for rescue surgical evacuation at various time points, including within 1 month and up to 24 months post-procedure. Clinical outcomes and complications are evaluated up to 24 months, with data collected on hospital stay duration, discharge condition, and any related complications. The study uses medical records and follow-up assessments to understand the long-term results of MMAE in treating cSDH.

CONDITIONS

Brief Title

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older
  • Patients who have received endovascular embolization of the middle meningeal artery using any of the following materials: PVA particles, Onyx, nBCA glue, dimethyl sulfoxide, microcoils, or PVA with microcoils
Not Eligible

You will not qualify if you...

  • Patients who have received endovascular embolization of the middle meningeal artery using any embolization materials other than those listed in the inclusion criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - Up to 24 months

Participants who have undergone middle meningeal artery embolization are observed for reaccumulation of hematoma, clinical outcomes, complications, and disposition after discharge over an extended period.

Follow-up visits within 1 month, between 1-3 months, 3-6 months, 6-12 months, and 12-24 months post procedure

Trial Site Locations

Total: 19 locations

1

Baptist Health South Florida, Inc.

Coral Gables, Florida, United States, 33143

Actively Recruiting

2

Mayo Clinic Florida

Jacksonville, Florida, United States, 32224

Completed

3

Orlando Regional Medical Center

Orlando, Florida, United States, 32806

Actively Recruiting

4

University of Illinois Chicago

Chicago, Illinois, United States, 60607

Completed

5

University of Chicago Medicine

Chicago, Illinois, United States, 60637

Actively Recruiting

6

The University of Iowa

Iowa City, Iowa, United States, 52242

Completed

7

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

8

Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School

Boston, Massachusetts, United States, 02215

Actively Recruiting

9

Lahey Hospital and Medical Center

Burlington, Massachusetts, United States, 01805

Actively Recruiting

10

Mayo Clinic

Rochester, Minnesota, United States, 55905

Completed

11

Montefiore Medical Center

The Bronx, New York, United States, 10467

Actively Recruiting

12

Geisinger Health

Danville, Pennsylvania, United States, 17822

Completed

13

Thomas Jefferson University

Philadelphia, Pennsylvania, United States, 19144

Actively Recruiting

14

UTHealth Houston

Houston, Texas, United States, 77030

Completed

15

HCA Houston Healthcare Kingwood

Kingwood, Texas, United States, 77339

Completed

16

Austin Health

Heidelberg, Victoria, Australia, 3084

Actively Recruiting

17

Unity Health Toronto

Toronto, Ontario, Canada, M5C 2T2

Completed

18

University of Toronto

Toronto, Ontario, Canada, M5S 1A1

Actively Recruiting

19

Toronto Western Hospital

Toronto, Ontario, Canada, M5T 2S8

Completed

Loading map...

Research Team

M

Muhammed Amir Essibayi, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Active 24 Hours Subperiostal vs. Passive Subdural Drainage A...

Chronic Subdural Hematoma

Actively Recruiting

4 locations

Randomized Trial Comparing Adjuvant Tranexamic Acid Versus S...

Chronic Subdural Hematoma

Actively Recruiting

1 location

Safety and Efficacy of Aspirin Continuation or Discontinuati...

Chronic Subdural Hematoma

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here